Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hor… Read more
Terns Pharmaceuticals Inc (TERN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.070x
Based on the latest financial reports, Terns Pharmaceuticals Inc (TERN) has a cash flow conversion efficiency ratio of -0.070x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.77 Million) by net assets ($284.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Terns Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Terns Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Terns Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Terns Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sega Sammy Holdings Inc
PINK:SGAMF
|
0.023x |
|
Nissin Foods Holdings Co.Ltd
F:NF2
|
0.054x |
|
PENNON GROUP NEW LS-6105
F:3PN
|
N/A |
|
TransAlta Corp
NYSE:TAC
|
0.156x |
|
NMDC Limited
NSE:NMDC
|
0.094x |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
-0.095x |
|
Siemens Limited
NSE:SIEMENS
|
0.028x |
|
Dabur India Limited
NSE:DABUR
|
0.067x |
Annual Cash Flow Conversion Efficiency for Terns Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Terns Pharmaceuticals Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $345.87 Million | $-70.02 Million | -0.202x | +23.29% |
| 2023-12-31 | $255.37 Million | $-67.39 Million | -0.264x | -48.82% |
| 2022-12-31 | $276.94 Million | $-49.11 Million | -0.177x | +32.04% |
| 2021-12-31 | $160.30 Million | $-41.83 Million | -0.261x | +39.96% |
| 2020-12-31 | $68.59 Million | $-29.81 Million | -0.435x | +87.97% |
| 2019-12-31 | $18.32 Million | $-66.22 Million | -3.614x | -1344.50% |
| 2018-12-31 | $72.23 Million | $-18.07 Million | -0.250x | -- |